Ask AI
ProCE Banner Activity

Key Clinical Decisions in Frontline Multiple Myeloma Management

Clinical Thought

In this commentary, an expert addresses key questions on evolving frontline therapy strategies, counseling patients about stem cell transplant, and individualizing treatment decisions in multiple myeloma.

Released: May 11, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from Johnson & Johnson and Sanofi.

Johnson & Johnson

Sanofi

Target Audience

This activity is intended for hematologists, oncologists, nurses, physician associates, pharmacists, and other healthcare professionals in VA medical centers caring for patients with multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Initiate timely systemic treatment for appropriate patients based on the latest MM diagnostic criteria, staging criteria, and risk factors

  • Synthesize current recommendations, approvals, clinical data, and patient factors to develop individualized treatment strategies leveraging anti-CD38–based regimens for patients with newly diagnosed MM

  • Design supportive care strategies to mitigate the risk of treatment-related adverse events

  • Implement strategies supporting equitable and timely initiation of therapy, access to novel therapies, and supportive care in Black and underserved patients with MM

Disclosure

Primary Author

Sarah A. Holstein, MD, PhD: researcher (paid to institution): Bristol Myers Squibb.